Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine.
Rena
R
Cooper-Kazaz
Aviva
A
Cohen
Bernard
B
Lerer
D000328:Adult; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000378:metabolism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage* / Q000009:adverse effects*; D009638:Norepinephrine / Q000378:metabolism; D000077593:Reboxetine; D012893:Sleep Wake Disorders / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism; D014284:Triiodothyronine / Q000008:administration & dosage* / Q000009:adverse effects*; D055815:Young Adult
D009025:Morpholines; D014284:Triiodothyronine; D000077593:Reboxetine; D009638:Norepinephrine